上皮性卵巢癌组织EDD和MRP2蛋白表达临床意义的研究

Expressions and clinical significance of EDD and MRP2 in epithelial ovarian cancer tissues

目的:通过检测EDD和MRP2蛋白在上皮性卵巢癌中的表达,探讨其与上皮性卵巢癌发生发展关系及其临床意义。方法:收集中山大学肿瘤防治中心1997-05-1-2003-12-31存档的上皮性卵巢癌术后组织石蜡标本72例、良性上皮性卵巢肿瘤组织石蜡标本15例和正常卵巢组织石蜡标本10例。应用免疫组化SP法检测EDD和MRP2蛋白在卵巢癌组织中的表达,并结合临床病理因素和预后进行分析。结果:EDD和MRP2蛋白在上皮性卵巢癌中的表达率分别为94.4%和54.2%,与正常卵巢组织和良性卵巢肿瘤相比,差异有统计学意义。EDD弱阳性表达的患者化疗有效率20.8%,EDD强阳性表达的患者化疗有效率65.9%,两组化疗缓解率差异无统计学意义,P=0.252。MRP2表达阴性的患者化疗缓解率为84.8%,MRP2表达阳性的患者化疗缓解率为59.0%,阴性表达组的化疗缓解率明显高于阳性表达组,P=0.016。结论:EDD蛋白的过度表达可能与上皮性卵巢癌的发生相关;MRP2蛋白在上皮性卵巢癌中的表达可能与肿瘤细胞固有的耐药相关,它在上皮性卵巢癌中的过度表达可能引起化疗耐药。

OBJECTIVE： To investigate the roles of EDD and MRP2 in the occurrence and development of the epithelial ovarian cancer and their clinical significance by detecting the expressions of EDD and MRP2 in epithelial ovarian cancer.METHODS： A retrospective study was performed including patients treated in the Caner Center of Sun Yat-Sen University from May 1,1997 to Dec.31,2003.The expressions of EDD and MRP2 were assayed with the immunohistochemistry in the tissue specimens of 72 patients with epithelial ovarian cancer,15 specimens of benign ovarian tumor and 10 normal ovarian tissues.The correlations of their expressions with the clinicpathological characteristics and prognosis of the patients were analyzed.RESULTS： The positive rates of EDD protein and MRP2 protein were 94.4% and 54.2% respectively in epithelial ovarian cancer and significantly higher in epithelial ovarian cancer than those in benign ovarian tumor and normal ovarian tissues.The response rate to chemotherapy of weak EDD positive groups was 20.8%,and strong EDD positive group was 65.9%.There were not significant differences between two groups（P=0.252）.The response rate to chemotherapy of the MRP2 positive group was 84.8%,and the negative group was 59.0%.The former was significantly lower（P=0.016）.CONCLUSIONS： Aberrant activated EDD may be related to tumorigenesis in ovarian cancer;The expression of MRP2 protein may be connected with the primary drug-resistance behavior of tumor cells.The overexpression of MRP2 may cause drug resistance in epithelial ovarian cancer.